in vivo

This whitepaper, brought to you by The Jackson Laboratory will teach: The benefits of the JAX NSGTM-MHC I/II KO mouse platform humanised with pre-characterised PBMCs How this platform can support a wide range of immunological studies, especially those containing T cells responses The versatility of this platform to various research disciplines

PerkinElmer has expanded its in vivo imaging portfolio with the launch of the Vega imaging system, an ultrasound platform that combines hands-free, automated technology with high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more.   The Vega system   The system eliminates challenges associated with conventional hand-held […]

An in vivo CRS Evaluation Study in humanised mouse models can deliver fast, reproducible, and translatable data about drug safety in just two weeks. A humanised mouse platform offers the unique ability to preclinically analyse a fully systemic response that involves human immune cells and surrounding tissues. Furthermore, the platform also allows for efficacy testing […]

Nykode Therapeutics (formerly Vaccibody) has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialisation of potential new vaccines for cancer and infectious diseases.  What is the structure of the agreement?  The agreement includes five programmes, three within cancer and two within infectious diseases. Each of these may include several vaccine candidates, all of […]

Covimro, a British biotech start-up, has developed a food-grade compound which has demonstrated its efficacy against the flu virus in an animal model study carried out by A-IR Clinical Research and Pharmidex Pharmaceutical Services.  The in vivo testing analysed Covimro’s antiviral capability against an infection of Influenza A H3N2, a flu variant consistent with the seasonal, non-lethal viruses familiar to humans. Once […]

Gamma Biosciences has agreed to make a controlling investment in Mirus Bio for nucleic acid delivery based in Madison, Wisconsin. The transaction will support Mirus’ plans to expand good manufacturing practice (GMP) production and commercialisation of its flagship product TransIT VirusGEN for large scale manufacturing of AAV and LV-based viral vectors for gene therapy, as […]